Trexquant Investment LP Boosts Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Trexquant Investment LP boosted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 22.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 481,607 shares of the company's stock after acquiring an additional 87,364 shares during the period. Trexquant Investment LP owned 0.22% of Hims & Hers Health worth $11,645,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health during the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Price Performance

NYSE HIMS traded up $1.17 during midday trading on Monday, hitting $27.16. 16,208,373 shares of the company traded hands, compared to its average volume of 14,738,906. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company's 50-day simple moving average is $39.82 and its 200-day simple moving average is $30.03. The company has a market cap of $6.03 billion, a PE ratio of 61.63 and a beta of 1.65.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 54,153 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70. Following the sale, the insider now owns 165,650 shares in the company, valued at $4,952,935. The trade was a 24.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 809,806 shares of company stock valued at $30,923,658 in the last 90 days. Insiders own 17.71% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on HIMS shares. Piper Sandler boosted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Bank of America increased their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Leerink Partners upped their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Finally, Needham & Company LLC increased their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and a consensus price target of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.